Work

Tislelizumab with anlotinib and chemotherapy for second-line treatment of pancreatic ductal adenocarcinoma: A phase II clinical trial.

Year: 2025

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e16394

Authors: Xuyuan Dong, Yinying Wu, Yangwei Fan, Yu Shi, Meichen Wang, Danfeng Dong, Li Enxiao

Institutions: First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410815588

FWCI:

Cites:

Cited by:

Related to: 10